The Community Guide

- gsearch

Search Results

Narrow Results:

2014 1
2012 1
2011 1
2007 1
2003 1

Journal Article 4
Letter 1

1 - 5 of 5 Results

Refine Results

Refine Results:

Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada

CITE Title : Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada Personal Author(s) : Clarke, Brian;Hiltz, Margot;Musgrave, Heather;Forward, Kevin R.; Published Date : Oct 2003 Source : Emerg Infect Dis. 9(10):1254-1259. URL : https://stacks.cdc.gov/view/cdc/14256 Clarke, Brian et al. (2003). Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada. 9(10). Clarke, Brian et al. "Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada" 9, no. 10 (2003) Clarke, Brian et al. "Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada" vol. 9, no. 10, 2003 Export RIS Citation Information.

:

Clarke, Brian ;

Hiltz, Margot

Oct 2003 | Emerg Infect Dis. 9(10):1254-1259.

No Description
Population-based Laboratory Surveillance for AmpC β-Lactamase–producing Escherichia coli, Calgary

CITE Title : Population-based Laboratory Surveillance for AmpC β-Lactamase–producing Escherichia coli, Calgary Personal Author(s) : Pitout, Johann D.D.;Gregson, Daniel B.;Church, Deirdre L.;Laupland, Kevin B.; Published Date : Mar 2007 Source : Emerg Infect Dis. 13(3):443-448. URL : https://stacks.cdc.gov/view/cdc/16323 Pitout, Johann D.D. et al. (2007). Population-based Laboratory Surveillance for AmpC β-Lactamase–producing Escherichia coli, Calgary. 13(3). Pitout, Johann D.D. et al. "Population-based Laboratory Surveillance for AmpC β-Lactamase–producing Escherichia coli, Calgary" 13, no. 3 (2007) Pitout, Johann D.D. et al. "Population-based Laboratory Surveillance for AmpC β-Lactamase–producing Escherichia coli, Calgary" vol. 13, no. 3, 2007 Export RIS Citation Information.

:

Pitout, Johann D.D. ;

Gregson, Daniel B.

Mar 2007 | Emerg Infect Dis. 13(3):443-448.

:

In the Calgary Health Region during 2000-2003, prospective, active, population-based laboratory surveillance for all cefoxitin-resistant Escherichia c...
Recurrent PID, Subsequent STI, and Reproductive Health Outcomes: Findings from the PID Evaluation and Clinical Health (PEACH) Study

CITE Title : Recurrent PID, Subsequent STI, and Reproductive Health Outcomes: Findings from the PID Evaluation and Clinical Health (PEACH) Study Personal Author(s) : Trent, Maria;Bass, Debra;Ness, Roberta B.;Haggerty, Catherine; Published Date : Sep 2011 Source : Sex Transm Dis. 38(9):879-881. URL : https://stacks.cdc.gov/view/cdc/33748 Trent, Maria et al. (2011). Recurrent PID, Subsequent STI, and Reproductive Health Outcomes: Findings from the PID Evaluation and Clinical Health (PEACH) Study. 38(9). Trent, Maria et al. "Recurrent PID, Subsequent STI, and Reproductive Health Outcomes: Findings from the PID Evaluation and Clinical Health (PEACH) Study" 38, no. 9 (2011) Trent, Maria et al. "Recurrent PID, Subsequent STI, and Reproductive Health Outcomes: Findings from the PID Evaluation and Clinical Health (PEACH) Study" vol. 38, no. 9, 2011 Export RIS Citation Information.

:

Trent, Maria ;

Bass, Debra

Sep 2011 | Sex Transm Dis. 38(9):879-881.

:

PEACH trial data were used to evaluate the relationship between subsequent sexually transmitted infection and recurrent pelvic inflammatory disease on...
Human MRSA Isolates with Novel Genetic Homolog, Germany

CITE Title : Human MRSA Isolates with Novel Genetic Homolog, Germany Personal Author(s) : Kriegeskorte, André;Ballhausen, Britta;Idelevich, Evgeny A.;Köck, Robin;Friedrich, Alexander W.;Karch, Helge;Peters, Georg;Becker, Karsten; Published Date : Jun 2012 Source : Emerg Infect Dis. 18(6):1016-1018. URL : https://stacks.cdc.gov/view/cdc/23569 Kriegeskorte, André et al. (2012). Human MRSA Isolates with Novel Genetic Homolog, Germany. 18(6). Kriegeskorte, André et al. "Human MRSA Isolates with Novel Genetic Homolog, Germany" 18, no. 6 (2012) Kriegeskorte, André et al. "Human MRSA Isolates with Novel Genetic Homolog, Germany" vol. 18, no. 6, 2012 Export RIS Citation Information.

:

Kriegeskorte, André ;

Ballhausen, Britta

Jun 2012 | Emerg Infect Dis. 18(6):1016-1018.

No Description
Rationale for Eliminating Staphylococcus Breakpoints for β-Lactam Agents Other Than Penicillin, Oxacillin or Cefoxitin, and Ceftaroline

CITE Title : Rationale for Eliminating Staphylococcus Breakpoints for β-Lactam Agents Other Than Penicillin, Oxacillin or Cefoxitin, and Ceftaroline Personal Author(s) : Bard, Jennifer Dien;Hindler, Janet A.;Gold, Howard S.;Limbago, Brandi; Published Date : Jan 22 2014 Source : Clin Infect Dis. 58(9):1287-1296. URL : https://stacks.cdc.gov/view/cdc/50572 Bard, Jennifer Dien et al. (2014). Rationale for Eliminating Staphylococcus Breakpoints for β-Lactam Agents Other Than Penicillin, Oxacillin or Cefoxitin, and Ceftaroline. 58(9). Bard, Jennifer Dien et al. "Rationale for Eliminating Staphylococcus Breakpoints for β-Lactam Agents Other Than Penicillin, Oxacillin or Cefoxitin, and Ceftaroline" 58, no. 9 (2014) Bard, Jennifer Dien et al. "Rationale for Eliminating Staphylococcus Breakpoints for β-Lactam Agents Other Than Penicillin, Oxacillin or Cefoxitin, and Ceftaroline" vol. 58, no. 9, 2014 Export RIS Citation Information.

:

Bard, Jennifer Dien ;

Hindler, Janet A.

Jan 22 2014 | Clin Infect Dis. 58(9):1287-1296.

:

Due to the ongoing concern about the reliability of Staphylococcus breakpoints (interpretive criteria) for other β-lactam agents, the Clinical and La...